236 related articles for article (PubMed ID: 32627316)
1. Effect of setmelanotide, a melanocortin-4 receptor agonist, on obesity in Bardet-Biedl syndrome.
Haws R; Brady S; Davis E; Fletty K; Yuan G; Gordon G; Stewart M; Yanovski J
Diabetes Obes Metab; 2020 Nov; 22(11):2133-2140. PubMed ID: 32627316
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period.
Haqq AM; Chung WK; Dollfus H; Haws RM; Martos-Moreno GÁ; Poitou C; Yanovski JA; Mittleman RS; Yuan G; Forsythe E; Clément K; Argente J
Lancet Diabetes Endocrinol; 2022 Dec; 10(12):859-868. PubMed ID: 36356613
[TBL] [Abstract][Full Text] [Related]
3. An evaluation of setmelanotide injection for chronic weight management in adult and pediatric patients with obesity due to Bardet-Biedl syndrome.
Lazareva J; Brady SM; Yanovski JA
Expert Opin Pharmacother; 2023 Apr; 24(6):667-674. PubMed ID: 37013719
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials.
Clément K; van den Akker E; Argente J; Bahm A; Chung WK; Connors H; De Waele K; Farooqi IS; Gonneau-Lejeune J; Gordon G; Kohlsdorf K; Poitou C; Puder L; Swain J; Stewart M; Yuan G; Wabitsch M; Kühnen P;
Lancet Diabetes Endocrinol; 2020 Dec; 8(12):960-970. PubMed ID: 33137293
[TBL] [Abstract][Full Text] [Related]
5. Interview-Based Patient- and Caregiver-Reported Experiences of Hunger and Improved Quality of Life with Setmelanotide Treatment in Bardet-Biedl Syndrome.
Ervin C; Norcross L; Mallya UG; Fehnel S; Mittleman RS; Webster M; Haqq AM; Haws RM
Adv Ther; 2023 May; 40(5):2394-2411. PubMed ID: 36961653
[TBL] [Abstract][Full Text] [Related]
6. Quality of life improvements following one year of setmelanotide in children and adult patients with Bardet-Biedl syndrome: phase 3 trial results.
Forsythe E; Haws RM; Argente J; Beales P; Martos-Moreno GÁ; Dollfus H; Chirila C; Gnanasakthy A; Buckley BC; Mallya UG; Clément K; Haqq AM
Orphanet J Rare Dis; 2023 Jan; 18(1):12. PubMed ID: 36647077
[TBL] [Abstract][Full Text] [Related]
7. The efficacy and safety of setmelanotide in individuals with Bardet-Biedl syndrome or Alström syndrome: Phase 3 trial design.
Haws RM; Gordon G; Han JC; Yanovski JA; Yuan G; Stewart MW
Contemp Clin Trials Commun; 2021 Jun; 22():100780. PubMed ID: 34013094
[TBL] [Abstract][Full Text] [Related]
8. Setmelanotide for the treatment of acquired hypothalamic obesity: a phase 2, open-label, multicentre trial.
Roth CL; Scimia C; Shoemaker AH; Gottschalk M; Miller J; Yuan G; Malhotra S; Abuzzahab MJ
Lancet Diabetes Endocrinol; 2024 Jun; 12(6):380-389. PubMed ID: 38697184
[TBL] [Abstract][Full Text] [Related]
9. Setmelanotide: First Approval.
Markham A
Drugs; 2021 Feb; 81(3):397-403. PubMed ID: 33638809
[TBL] [Abstract][Full Text] [Related]
10. Setmelanotide: a promising advancement for pediatric patients with rare forms of genetic obesity.
Trapp CM; Censani M
Curr Opin Endocrinol Diabetes Obes; 2023 Apr; 30(2):136-140. PubMed ID: 36722447
[TBL] [Abstract][Full Text] [Related]
11. Quality of life outcomes in two phase 3 trials of setmelanotide in patients with obesity due to LEPR or POMC deficiency.
Kühnen P; Wabitsch M; von Schnurbein J; Chirila C; Mallya UG; Callahan P; Gnanasakthy A; Poitou C; Krabusch PM; Stewart M; Clément K
Orphanet J Rare Dis; 2022 Feb; 17(1):38. PubMed ID: 35123544
[TBL] [Abstract][Full Text] [Related]
12. Understanding the Patient Experience of Hunger and Improved Quality of Life with Setmelanotide Treatment in POMC and LEPR Deficiencies.
Wabitsch M; Fehnel S; Mallya UG; Sluga-O'Callaghan M; Richardson D; Price M; Kühnen P
Adv Ther; 2022 Apr; 39(4):1772-1783. PubMed ID: 35192151
[TBL] [Abstract][Full Text] [Related]
13. Setmelanotide for controlling weight and hunger in Bardet-Biedl syndrome.
Tauber M
Lancet Diabetes Endocrinol; 2022 Dec; 10(12):829-830. PubMed ID: 36356611
[No Abstract] [Full Text] [Related]
14. Caregiver burden in Bardet-Biedl syndrome: findings from the CARE-BBS study.
Forsythe E; Mallya UG; Yang M; Huber C; Cala ML; Greatsinger A; Hagopian E; Pomeroy J; Haqq AM
Orphanet J Rare Dis; 2023 Jul; 18(1):181. PubMed ID: 37415214
[TBL] [Abstract][Full Text] [Related]
15. Proopiomelanocortin Deficiency Treated with a Melanocortin-4 Receptor Agonist.
Kühnen P; Clément K; Wiegand S; Blankenstein O; Gottesdiener K; Martini LL; Mai K; Blume-Peytavi U; Grüters A; Krude H
N Engl J Med; 2016 Jul; 375(3):240-6. PubMed ID: 27468060
[TBL] [Abstract][Full Text] [Related]
16. Burden of hyperphagia and obesity in Bardet-Biedl syndrome: a multicountry survey.
Forsythe E; Mallya UG; Yang M; Huber C; Cala ML; Greatsinger A; Hagopian E; Pomeroy J; Haqq AM
Orphanet J Rare Dis; 2023 Jul; 18(1):182. PubMed ID: 37415189
[TBL] [Abstract][Full Text] [Related]
17. Setmelanotide (Imcivree) for rare genetic forms of obesity.
Med Lett Drugs Ther; 2021 Jul; 63(1629):e3-e4. PubMed ID: 34544109
[No Abstract] [Full Text] [Related]
18. Hyperphagia among patients with Bardet-Biedl syndrome.
Sherafat-Kazemzadeh R; Ivey L; Kahn SR; Sapp JC; Hicks MD; Kim RC; Krause AJ; Shomaker LB; Biesecker LG; Han JC; Yanovski JA
Pediatr Obes; 2013 Oct; 8(5):e64-7. PubMed ID: 23776152
[TBL] [Abstract][Full Text] [Related]
19. Setmelanotide: A Novel Targeted Treatment for Monogenic Obesity.
Pressley H; Cornelio CK; Adams EN
J Pharm Technol; 2022 Dec; 38(6):368-373. PubMed ID: 36311304
[No Abstract] [Full Text] [Related]
20. Diabetes mellitus in Bardet Biedl syndrome.
Pomeroy J; Offenwanger KM; Timmler T
Curr Opin Endocrinol Diabetes Obes; 2023 Feb; 30(1):27-31. PubMed ID: 36476576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
